| Name | Title | Contact Details |
|---|
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.
Attenua, Inc. is a pharmaceutical company developing antitussive medications.
Allichem is a Savage, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MiddleBrook Pharmaceuticals, Inc. is a Westlake, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Golden Sap is a Sainte-Aurí©lie, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.